70 related articles for article (PubMed ID: 1877838)
1. [A case of malignant hemangioendothelioma effectively treated with intra-arterial continuous infusion of interleukin-2].
Fujioka A; Sugitani M; Suzuki Z; Tokita J; Yorimitsu K; Sezai Y
Gan To Kagaku Ryoho; 1991 Aug; 18(11):1958-61. PubMed ID: 1877838
[TBL] [Abstract][Full Text] [Related]
2. [A case of malignant hemangioendothelioma effectively treated with intra-arterial continuous infusion of interleukin-2].
Fujioka A; Sezai Y
Nihon Hifuka Gakkai Zasshi; 1991 Aug; 101(9):959-63. PubMed ID: 1942594
[TBL] [Abstract][Full Text] [Related]
3. [A dramatic effect of continuous intra-arterial injected recombinant interleukin-2 immunotherapy on malignant hemangioendothelioma].
Takano M; Suzuki Y; Asai T; Masuzawa M; Nishiyama S
Nihon Hifuka Gakkai Zasshi; 1991 Jun; 101(7):719-25. PubMed ID: 1942580
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
5. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
7. [The effect of IL-2 injection around the metastatic cervical lymphnode].
Ogasawara H; Takeda N; Takeda N; Kumoi T
Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1119-22. PubMed ID: 2398297
[TBL] [Abstract][Full Text] [Related]
8. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
[TBL] [Abstract][Full Text] [Related]
9. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer].
Ikawa T; Eura M; Fukiage T; Murakami H; Yamasaki S; Fukuda K; Fukushima M; Arishima S; Maehara T; Ishikawa T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1438-47. PubMed ID: 2786378
[TBL] [Abstract][Full Text] [Related]
10. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
11. The phenotypic changes in tumour infiltrating lymphocytes and tumour cells following intra-arterial infusion of interleukin-2 in patients with squamous cell carcinoma.
Salter J; Maclennan KA; Moore J; Dadian G; Riches PG; Gore ME
J Pathol; 1995 Jun; 176(2):167-73. PubMed ID: 7636627
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
[TBL] [Abstract][Full Text] [Related]
13. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].
Duan DS
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):281-3, 314. PubMed ID: 8192930
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
15. [Intrapleural transfer of LAK cells combined with rIL-2 in the treatment of advanced lung cancer with malignant pleural effusion].
Li DJ
Zhonghua Zhong Liu Za Zhi; 1989 Jul; 11(4):294-6. PubMed ID: 2625114
[TBL] [Abstract][Full Text] [Related]
16. Local/regional recombinant interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous infusion of rIL-2 in bladder cancer patients: a phase I study.
Velotti F; Tubaro A; Stoppacciaro A; Pettinato A; Morrone S; Bossola P; Napolitano T; Miano L; Ruco L; Piccoli M
Ann Ist Super Sanita; 1990; 26(3-4):411-21. PubMed ID: 2091503
[TBL] [Abstract][Full Text] [Related]
17. A murine model for the immunotherapy of head and neck squamous cell carcinoma.
Hier MP; Black MJ; Shenouda G; Sadeghi N; Karp SE
Laryngoscope; 1995 Oct; 105(10):1077-80. PubMed ID: 7564839
[TBL] [Abstract][Full Text] [Related]
18. [A phase 2 study of recombinant interleukin 2 (S-6820) for head and neck cancer].
Sawaki S
Gan No Rinsho; 1990 Feb; 36(2):111-20. PubMed ID: 2308207
[TBL] [Abstract][Full Text] [Related]
19. Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells.
Clayman GL; Taylor DL; Liu FJ; Lavedan P; Savage HE; Schantz SP
Laryngoscope; 1993 Mar; 103(3):299-307. PubMed ID: 7680086
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
